Su1816 Presence of Colonic Dysplasia prior to Colorectal Cancer Diagnosis is Associated with Early Stage Cancer among Patients with Inflammatory Bowel Disease: A National Cohort Study

2016 ◽  
Vol 150 (4) ◽  
pp. S561 ◽  
Author(s):  
Ami J. Panara ◽  
Hao Chi Zhang ◽  
Akbar K. Waljee ◽  
Jill Gaidos ◽  
Linda A. Feagins ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Inflammatory Bowel Disease ◽  
Cohort Study ◽  
Cancer Diagnosis ◽  
Bowel Disease ◽  
Early Stage ◽  
Early Stage Cancer ◽  
National Cohort ◽  
Inflammatory Bowel

Risk of a post-colonoscopy colorectal cancer diagnosis in patients with inflammatory bowel disease: a population-based cohort study

Endoscopy ◽  
2020 ◽  
Author(s):  
Frederikke Schønfeldt Troelsen ◽  
Henrik Toft Sørensen ◽  
Lars Pedersen ◽  
Rune Erichsen
Keyword(s):  
Colorectal Cancer ◽  
Inflammatory Bowel Disease ◽  
Cohort Study ◽  
Cancer Diagnosis ◽  
Bowel Disease ◽  
Population Based ◽  
Colorectal Cancers ◽  
Point Estimates ◽  
Inflammatory Bowel ◽  
First Time

Background and study aims: Post-colonoscopy colorectal cancers (PCCRCs) may account for up to 50% of all colorectal cancers (CRCs) diagnosed in patients with inflammatory bowel disease (IBD). This may reflect a high colonoscopy frequency; however evidence remains limited. Patient and methods: We conducted a cohort study of IBD and non-IBD patients undergoing colonoscopy. We calculated 6-36 months CIPs of PCCRC after first-time and subsequent colonoscopies. We also computed crude and adjusted HRs of PCCRC, comparing IBD with non-IBD patients undergoing first-time and subsequent colonoscopies. Separate analyses were conducted for consecutive colonoscopies. We calculated PCCRC-3 year rates to estimate the proportion of IBD and non-IBD CRC patients experiencing PCCRC. Results: We observed 138 and 1,909 PCCRCs among 34,688 IBD and 358,217 non-IBD patients who underwent colonoscopy. The CIP of PCCRC after first-time colonoscopy was 0.21%, 95% confidence interval (CI): [0.17-0.27] for IBD patients and 0.37%, 95% CI: [0.35-0.39] for non-IBD patients. The adjusted HR of PCCRC after a first-time colonoscopy was 0.96, 95% CI: [0.75-1.22] and the adjusted HRs after subsequent colonoscopies had point estimates around 1.0. The PCCRC-3 year rate was 24.3%, 95% CI: [20.4-28.7] for IBD and 7.5%, 95% CI [7.2-7.8] for non-IBD patients. Conclusions: Although PCCRCs accounted for a substantial proportion of all IBD-related CRCs, IBD patients had a low CIP of PCCRC after colonoscopy. The elevated PCCRC-3 year rates may among other factors stem from increased colonoscopy frequency in IBD patients.

The Incidence and Prevalence of Inflammatory Bowel Disease Among Veterans: A National Cohort Study

2011 ◽  
Vol 106 ◽  
pp. S491
Author(s):  
Jason Hou ◽  
Jennifer Kramer ◽  
Peter Richardson ◽  
Minghua Mei ◽  
Hashem EL-Serag
Keyword(s):  
Inflammatory Bowel Disease ◽  
Cohort Study ◽  
Bowel Disease ◽  
National Cohort ◽  
Inflammatory Bowel

Colorectal cancer

2016 ◽  
pp. 444-477
Author(s):  
Alex Boussioutas ◽  
Stephen Fox ◽  
Iris Nagtegaal ◽  
Alexander Heriot ◽  
Jonathan Knowles ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Risk Factors ◽  
Inflammatory Bowel Disease ◽  
Colon Cancer ◽  
Bowel Disease ◽  
Colonic Cancer ◽  
Early Stage ◽  
Inflammatory Bowel ◽  
Resected Stage ◽  
Stage Ii Colon Cancer

This chapter covers colorectal cancer, and includes information on epidemiology, risk factors (chronic inflammation/inflammatory bowel disease, radiation, diet and lifestyle, post cholecystectomy, diabetes, obesity and insulin resistance, cigarette smoking, alcohol, ureterocolic anastamosis, and genetic risk factors, screening, and chemoprevention (aspirin, and NSAIDS), the molecular biology and pathology of colorectal cancer, colorectal carcinoma (location, pathologic prognostic markers, and predictive markers), surgical management (colonic cancer and inflammatory bowel disease, hereditary non-polyposis colonic cancer or HNPCC, presenting as an emergency, treatment of polyp or early cancers, liver and lung metastasis, peritoneal disease, results of surgery and treatment for colon cancer, medical management of early stage disease, adjuvant chemotherapy for stage III disease (T1-4, N1-2M0), adjuvant therapy of patients with resected stage II colon cancer, radiotherapy, multidisciplinary care and special groups, the role of allied teams, and surveillance and follow-up.

Sign in / Sign up

Export Citation Format

Share Document